New

FAQs

Frequently asked questions

1) What is GenoSure^® MG?
GenoSure^® MG is an HIV-1 genotypic resistance assay which combines the best features of LabCorp’s GenoSure^® assay and Monogram’s GeneSeq^® assay.

2) What are some of GenoSure^® MG’s features?
Some of the features are:

An updated algorithm with weighted scoring for making assessments (new)
A faster turnaround time: 7 days (new)
A three-tier assessment: resistance, resistance possible, and sensitive (new)
Sequencing of reverse transcriptase to amino acid 400 (new)
A 500 copy/mL viral load requirement (maintained)
An ability to detect mixtures as low as 10% (maintained)

3) Is GenoSure^® MG a virtual phenotype? What is the difference?
Genosure^® MG is not a virtual phenotype. GenoSure^® MG does not provide a “prediction” of fold change which is a requirement for virtual phenotyping. GenoSure^® MG has a single cutoff which is based on phenotypic outcome datasets.

4) When should I use GenoSure^® MG?
GenoSure^® MG should be used for the same clinical situations in which GeneSeq^® or GenoSure^® is used. The Department of Health and Human Services, International AIDS Society, and the American Academy of HIV Medicine each provide guidelines for the use and frequency of HIV-1 resistance testing for the selection of antiretroviral regimens.

5) If I had a GeneSeq^® in the past, should a new GenoSure^® MG be ordered?
The use of GenoSure^® MG should be considered if clinically necessary. Retesting is not recommended unless there is a change in clinical conditions that warrants a new resistance test.

New report
format with an
intermediate
resistance
category.
Learn more

GeneSeq^® and GenoSure^™
have been replaced by